Avalo Therapeutics, Inc.
AVTXNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $302.16M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $11.21$24.27
- Volume (live)
- -
- Avg. volume (3M)
- 2.09M
Avalo Therapeutics (AVTX) Stock Price & Financial Analysis
Avalo Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $6.53 - $7.50 |
|---|---|
| 52-Week High | $24.27 |
| 52-Week Low | $11.21 |
| Open | $7.27 |
| Volume (last close) | 4.55M |
| Average Volume (3M) | 2.09M |
| Revenue (TTM) | 59.00K |
|---|---|
| Net Income (TTM) | -100.33M |
| Free Cash Flow (TTM) | -68.29M |
| EPS (TTM) | −$4.18 |
| Profit Margin | -170055.93% |
| Operating Margin | -154844.07% |
| Return on Equity (ROE) | -22.36% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 302.16M |
|---|---|
| Shares Outstanding | 43.60M |
| Price to Sales (P/S) | 5121.39 |
| Price to Book (P/B) | 0.67 |
| EV/EBITDA | -2.66 |
| 50-Day MA | $16.70 |
|---|---|
| 200-Day MA | $16.39 |
| 1-Year Change | −58.43% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Avalo Therapeutics at a Glance
As of the Oct 23, 2026 close, Avalo Therapeutics (AVTX) has a market capitalization of $302.16M. The stock trades at 5121.4× sales. Over the trailing twelve months it lost $100.33M on revenue of $59.00K and burned $68.29M of free cash flow. Revenue fell 86.6% year over year.
As of its latest reported balance sheet, it holds $85.38M in cash and securities against $242.00K of debt, a net cash position of $85.14M.
Avalo Therapeutics does not currently pay a dividend.
The share price is down 58.4% over the past year. At $6.93 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $11.21 to $24.27, below its 200-day moving average of $16.39.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $34.17, 393.1% above the Oct 23, 2026 close.
Frequently Asked Questions About Avalo Therapeutics
What is the current stock price for AVTX?
As of the Oct 23, 2026 close, AVTX stock trades at $6.93. The 52-week range is $11.21–$24.27, with a day range of $6.53–$7.50.
What is the P/E ratio for AVTX?
The P/E ratio (Price-to-Earnings) for AVTX is shown in the Key Statistics section. This valuation metric helps compare Avalo Therapeutics, Inc. to industry peers.
Does AVTX pay dividends?
Avalo Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AVTX?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for AVTX is Buy. The average 12-month price target is $34.17, a 393.1% upside from the Oct 23, 2026 close of $6.93.
What is the market cap of AVTX?
As of the Oct 23, 2026 close, Avalo Therapeutics's market capitalization is $302.2M, classifying it as a small-cap company. Avalo Therapeutics operates in the Healthcare sector within the Biotechnology industry.